HEAR IT FIRST WITH OUR DAILY NEWSLETTER



We don't spam. Learn more about our Privacy Policy

Special Report: Australian biotech company Cynata Therapeutics has taken an exciting step forward in the quest to eradicate cancer with the use of its proprietary mesenchymal stem cell (MSC) technology.

The ASX-listed researcher (ASX:CYP) has successfully produced genetically-engineered MSCs using the proprietary Cymerus platform technology to express therapeutic anti-cancer agents.

MSCs are adult stem cells that can be isolated from human or animal sources to produce more than one kind of specialist cell.

Cynata’s Cymerus technology enables the production of therapeutic MSCs at an economic and commercial scale without requiring multiple donors or massive expansion of the MSCs in culture, overcoming a critical shortcoming of current methods.

Cynata’s preclinical trials showed MSCs can be effectively tracked by real time imaging in vivo in mouse tumour models and showed highly promising therapeutic benefits in different mouse tumour models.

“These highly encouraging results suggest that the Cymerus platform can be exploited to produce targeted anti-cancer therapies, which may have significant advantages over conventional cancer treatments, from both a safety and efficacy perspective,” said Dr Kilian Kelly, Cynata’s Vice President of Product Development.

Dr Kelly says the results suggest Cymerus can be utilised to produce cancer-fighting therapies with safety and efficacy improvements on existing treatments.

“Importantly, this engineering technique could also facilitate the creation of novel engineered therapies for areas of high unmet need in other therapeutic areas.”

Professor Khalid Shah, Vice Chair of Research at Brigham and Women’s Hospital in Boston, Massachusetts, and Director of the Center for Stem Cell Therapeutics and Imaging at Harvard Medical School, directed the study.

Professor Shah said the results support the cell-based approach.

“It provides a continuous pool of therapeutic protein around the tumour cells, circumventing the protein short half-lives. Overall, the study outcomes support the use of engineered Cymerus MSCs for cell therapy to target various malignancies.”

Cynata said it intends to continue pursuing the new approach for cancer treatment as part of its pipeline.

 

 

This special report is brought to you by Cynata Therapeutics.

This advice has been prepared without taking into account your objectives, financial situation or needs. You should, therefore, consider the appropriateness of the advice, in light of your own objectives, financial situation or needs, before acting on the advice. If this advice relates to the acquisition, or possible acquisition, of a particular financial product, the recipient should obtain a disclosure document, a Product Disclosure Statement or an offer document (PDS) relating to the product and consider the PDS before making any decision about whether to acquire the product.